Cited by 481Melanoma and MAPK PathwaysLung Cancer Treatments and MutationsProtein Tyrosine Phosphatases

The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.

MAP Kinase Pathway Alterations in BRAF -Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

Open access

Wagle, Nikhil, Van Allen, Eliezer M., Treacy, Daniel J., Frederick, Dennie T., Cooper, Zachary A., Taylor-Weiner, Amaro, Rosenberg, Mara, Goetz, Eva M., Sullivan, Ryan J., Farlow, Deborah N., Friedrich, Dennis C., Anderka, Kristin, Perrin, Danielle, Johannessen, Cory M., McKenna, Aaron, Cibulskis, Kristian, Kryukov, Gregory, Hodis, Eran, Lawrence, Donald P., Fisher, Sheila, Getz, Gad, Gabriel, Stacey B., Carter, Scott L., Flaherty, Keith T., Wargo, Jennifer A., Garraway, Levi A.·2014·Cancer Discovery

DOI 10.1158/2159-8290.cd-13-0631PMC PMC3947296

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Treatment of BRAF-mutant melanoma with combined dabrafenib and trametinib, which target RAF and the downstream MAP–ERK kinase (MEK)1 and MEK2 kinases, respectively, improves progression-free survival and response rates compared with dabrafenib monotherapy. Mechanisms of clinical resistance to combined RAF/MEK inhibition are unknown. We performed whole-exome sequencing (WES) and whole-transcriptome sequencing (RNA-seq) on pretreatment and drug-resistant tumors from five patients with acquired resistance to dabrafenib/trametinib. In three of these patients, we identified additional mitogen-activated protein kinase (MAPK) pathway alterations in the resistant tumor that were not detected in the pretreatment tumor, including a novel activating mutation in MEK2 (MEK2Q60P). MEK2Q60P conferred resistance to combined RAF/MEK inhibition in vitro, but remained sensitive to inhibition of the downstream kinase extracellular signal–regulated kinase (ERK). The continued MAPK signaling-based resistance identified in these patients suggests that alternative dosing of current agents, more potent RAF/MEK inhibitors, and/or inhibition of the downstream kinase ERK may be needed for durable control of BRAF-mutant melanoma. Significance: This study represents an initial clinical genomic study of acquired resistance to combined RAF/MEK inhibition in BRAF-mutant melanoma, using WES and RNA-seq. The presence of diverse resistance mechanisms suggests that serial biopsies and genomic/molecular profiling at the time of resistance may ultimately improve the care of patients with resistant BRAF-mutant melanoma by specifying tailored targeted combinations to overcome specific resistance mechanisms. Cancer Discov; 4(1); 61–8. ©2013 AACR. See related commentary by Solit and Rosen, p. 27 This article is highlighted in the In This Issue feature, p. 1

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-13-0631

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citation
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Self-citation
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Self-citation
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,244
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,205
Self-citation
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
Self-citation
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771
Self-citation
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
Self-citation
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454
Self-citation

Show all 27 references

Sorted by citations

Items 101–200 of 481

Understanding the Genetic Mechanisms of Cancer Drug Resistance Using Genomic Approaches
Hu, X., & Zhang, Z. (2015) · Trends in Genetics · doi:10.1016/j.tig.2015.11.003 · Cited by 94
The ERK cascade inhibitors: Towards overcoming resistance
Maik-Rachline, G., & Seger, R. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2015.12.001 · Cited by 91
Plasticity of Extrachromosomal and Intrachromosomal BRAF Amplifications in Overcoming Targeted Therapy Dosage Challenges
Song, K., Minami, J. K., Huang, A. J. Y., Dehkordi, S. R., Lomeli, S. H., Luebeck, J., Goodman, M. H., Moriceau, G., Krijgsman, O., Dharanipragada, P., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0936 · Cited by 85
Translating insights into tumor evolution to clinical practice: promises and challenges
Fittall, M. W., & Loo, P. V. (2019) · Genome Medicine · doi:10.1186/s13073-019-0632-z · Cited by 91
Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies
Leto, S. M., & Trusolino, L. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1161-2 · Cited by 87
Role of miRNAs in Melanoma Metastasis
Gajos-Michniewicz, A., & Czyż, M. (2019) · Cancers · doi:10.3390/cancers11030326 · Cited by 90
Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma
Shen, C., Kim, S. H., Trousil, S., Frederick, D. T., Piris, A., Yuan, P., Cai, L., Gu, L., Li, M., Lee, J. H., et al. (2016) · Nature Medicine · doi:10.1038/nm.4155 · Cited by 86
Self-citation
A slow-cycling subpopulation of melanoma cells with highly invasive properties
Perego, M., Maurer, M., Wang, J., Shaffer, S. M., Müller, A. C., Parapatics, K., Li, L., Hristova, D. M., Shin, S. A., Keeney, F., et al. (2017) · Oncogene · doi:10.1038/onc.2017.341 · Cited by 86
Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review
Tangella, L. P., Clark, M. E., & Gray, E. S. (2020) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2020.129736 · Cited by 92
The Emerging Role of TYRO3 as a Therapeutic Target in Cancer
Smart, S. K., Vasileiadi, E., Wang, X., DeRyckere, D., & Graham, D. K. (2018) · Cancers · doi:10.3390/cancers10120474 · Cited by 87
MAPK kinase signalling dynamics regulate cell fate decisions and drug resistance
Rauch, N., Rukhlenko, O. S., Kölch, W., & Kholodenko, B. Ν. (2016) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.07.019 · Cited by 86
BRAFV600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts
Kemper, K., Krijgsman, O., Kong, X., Cornelissen‐Steijger, P., Shahrabi, A., Weeber, F., Velden, D. L. V. D., Bleijerveld, O. B., Kuilman, T., Kluin, R. J. C., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.064 · Cited by 81
Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines
Garman, B., Anastopoulos, I. N., Krepler, C., Brafford, P. A., Sproesser, K., Jiang, Y., Wubbenhorst, B. S., Amaravadi, R. K., Bennett, J., Beqiri, M., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.052 · Cited by 79
Self-citation
MED12 methylation by CARM1 sensitizes human breast cancer cells to chemotherapy drugs
Wang, L., Zeng, H., Wang, Q., Zhao, Z., Boyer, T., Bian, X., & Xu, W. (2015) · Science Advances · doi:10.1126/sciadv.1500463 · Cited by 80
Fisetin, a dietary flavonoid, augments the anti-invasive and anti-metastatic potential of sorafenib in melanoma
Pal, H. C., Diamond, A. C., Strickland, L. R., Kappes, J. C., Katiyar, S. K., Elmets, C. A., Athar, M., & Afaq, F. (2015) · Oncotarget · doi:10.18632/oncotarget.6237 · Cited by 81
Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cells
Loria, R., Bon, G., Perotti, V., Gallo, E., Bersani, I., Baldassari, P., Porru, M., Leonetti, C., Carlo, S. E. D., Visca, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2995 · Cited by 80
Conjunctival melanoma: New insights in tumour genetics and immunology, leading to new therapeutic options
Brouwer, N. J., Verdijk, R. M., Heegaard, S., Marinkovic, M., Esmaeli, B., & Jager, M. J. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100971 · Cited by 81
Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma
Lassen, A., Atefi, M. S., Robert, L., Wong, D. J. L., Cerniglia, M., Comin-Anduix, B., & Ribas, A. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-83 · Cited by 81
Comparison of Custom Capture for Targeted Next-Generation DNA Sequencing
Samorodnitsky, E., Datta, J., Jewell, B. M., Hagopian, R., Miya, J., Wing, M. R., Damodaran, S., Lippus, J. M., Reeser, J. W., Bhatt, D., et al. (2014) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.09.009 · Cited by 77
Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ -Driven Uveal Melanoma
Paradis, J. S., Acosta, M., Saddawi‐Konefka, R., Kishore, A., Lubrano, S., Gomes, F., Arang, N., Tiago, M., Coma, S., Wu, X., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3363 · Cited by 81
Long-term outcome in BRAFV600E melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression
Puzanov, I. J., Amaravadi, R. K., McArthur, G. A., Flaherty, K. T., Chapman, P. B., Sosman, J. A., Ribas, A., Shackleton, M. J., Hwu, P., Chmielowski, B., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.04.010 · Cited by 77
Self-citation
Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma
Queirolo, P., Picasso, V., & Spagnolo, F. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.04.010 · Cited by 77
Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAF V600E Colorectal Cancer
Hazar-Rethinam, M. H., Kleyman, M., Han, G. C., Liu, D., Ahronian, L. G., Shahzade, H. A., Chen, L., Parikh, A. R., Allen, J. N., Clark, J. W., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1227 · Cited by 77
Vitexin compound 1, a novel extraction from a Chinese herb, suppresses melanoma cell growth through DNA damage by increasing ROS levels
Liu, N., Wang, K. S., Qi, M., Zhou, Y. J., Zeng, G. Y., Tao, J., Zhou, J., Zhang, J. L., Chen, X., & Peng, C. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0897-x · Cited by 73
Protein–Protein Interactions: Emerging Oncotargets in the RAS-ERK Pathway
García-Gómez, R., Bustelo, X. R., & Crespo, P. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.07.002 · Cited by 72
Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAF V600E-Mutant Melanoma
Eroglu, Z., Chen, Y. A., Gibney, G. T., Weber, J. S., Kudchadkar, R. R., Khushalani, N. I., Markowitz, J., Brohl, A. S., Tetteh, L. F., Ramadan, H., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0565 · Cited by 74
TGF-β in the microenvironment induces a physiologically occurring immune-suppressive senescent state
Matsuda, S., Revandkar, A., Dubash, T. D., Ravi, A., Wittner, B. S., Lin, M., Morris, R. T., Burr, R., Guo, H., Seeger, K., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112129 · Cited by 76
Self-citation
Nras in melanoma: Targeting the undruggable target
Mandalà, M., Merelli, B., & Massi, D. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.05.005 · Cited by 74
The discovery and development of binimetinib for the treatment of melanoma
Tran, B., & Cohen, M. S. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1746265 · Cited by 77
Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma
Carlino, M. S., Long, G. V., Kefford, R. F., & Rizos, H. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.021 · Cited by 72
Tumor Heterogeneity and Therapeutic Resistance
Lovly, C. M., Salama, A. K. S., & Salgia, R. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_158808 · Cited by 74
Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy
Ahronian, L. G., & Corcoran, R. B. (2017) · Genome Medicine · doi:10.1186/s13073-017-0431-3 · Cited by 67
Targeted Therapy Resistance Mechanisms and Therapeutic Implications in Melanoma
Chen, G., & Davies, M. A. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.03.001 · Cited by 66
Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
Azimi, A., Caramuta, S., Seashore-Ludlow, B. A., Boström, J., Robinson, J. L., Edfors, F., Tuominen, R., Kemper, K., Krijgsman, O., Peeper, D. S., et al. (2018) · Molecular Systems Biology · doi:10.15252/msb.20177858 · Cited by 66
ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy
Jaiswal, B. S., Durinck, S., Stawiski, E. W., Yin, J., Wang, W., Lin, E., Moffat, J. G., Martin, S. E., Modrusan, Z. D., & Seshagiri, S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3674 · Cited by 69
Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma
Wang, B., Zhang, W., Zhang, G., Kwong, L., Lu, H., Tan, J., Sadek, N., Xiao, M., Zhang, J., Labrie, M., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01911-5 · Cited by 66
The RAF-MEK-ERK Pathway: Targeting ERK to Overcome Obstacles of Effective Cancer Therapy
Yu, Z., Ye, S., Hu, G., Lv, M., Tu, Z., Zhou, K., & Li, Q. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.14.143 · Cited by 66
Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia
Murali, I., Kasar, S. N., Naeem, A. S., Tyekucheva, S., Khalsa, J. K., Thrash, E. M., Itchaki, G., Livitz, D. G., Leshchiner, I., Dong, S., et al. (2021) · Blood · doi:10.1182/blood.2020006765 · Cited by 66
Self-citation
Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
Hong, A., Piva, M., Liu, S., Hugo, W., Lomeli, S. H., Zoete, V., Randolph, C. E., Yang, Z., Wang, Y., Lee, J. J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0873 · Cited by 64
Patterns of genomic evolution in advanced melanoma
Birkeland, E. E., Zhang, S., Poduval, D. B., Geisler, J., Nakken, S., Vodák, D., Meza‐Zepeda, L. A., Hovig, E. J., Myklebost, O., Knappskog, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05063-1 · Cited by 62
Gene isoforms as expression-based biomarkers predictive of drug response in vitro
Safikhani, Z., Smirnov, P., Thu, K. L., Silvester, J., El-Hachem, N., Quevedo, R., Lupien, M., Mak, T. W., Cescon, D. W., & Haibe‐Kains, B. (2017) · Nature Communications · doi:10.1038/s41467-017-01153-8 · Cited by 60
Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma
Fofaria, N. M., Frederick, D. T., Sullivan, R. J., Flaherty, K. T., & Srivastava, S. (2015) · Oncotarget · doi:10.18632/oncotarget.5755 · Cited by 66
Self-citation
Oncogene-dependent sloppiness in mRNA translation
Champagne, J., Pataskar, A., Blommaert, N., Nagel, R., Wernaart, D., Ramalho, S., Kenski, J. C. N., Bleijerveld, O. B., Zaal, E. A., Berkers, C. R., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.09.002 · Cited by 64
Targeted inhibition of metastatic melanoma through interference with Pin1-FOXM1 signaling
Kruiswijk, F., Hasenfuss, S. C., Sivapatham, R., Baar, M. P., Putavet, D. A., Naipal, K. A. T., van den Broek, N. J. F., Kruit, W. H. J., van der Spek, P. J., van Gent, D. C., et al. (2015) · Oncogene · doi:10.1038/onc.2015.282 · Cited by 62
Modeling of signaling crosstalk-mediated drug resistance and its implications on drug combination
Sun, X., Bao, J., You, Z., Chen, X., & Cui, J. (2016) · Oncotarget · doi:10.18632/oncotarget.11745 · Cited by 59
Clinical responses to ERK inhibition in BRAF V600E-mutant colorectal cancer predicted using a computational model
Kirouac, D. C., Schaefer, G., Chan, J., Merchant, M., Orr, C., Huang, S.-M. A., Moffat, J., Liu, L., Gadkar, K., & Ramanujan, S. (2017) · npj Systems Biology and Applications · doi:10.1038/s41540-017-0016-1 · Cited by 60
Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy
Smalley, K. S. M., Smalley, I., Kenchappa, R. S., Sahebjam, S., & Forsyth, P. A. (2016) · International Journal of Cancer · doi:10.1002/ijc.30147 · Cited by 60
Beyond the BRAF V 600E hotspot: biology and clinical implications of rare BRAF gene mutations in melanoma patients
Richtig, G., Höeller, C., Kashofer, K., Aigelsreiter, A. M., Heinemann, A., Kwong, L. N., Pichler, M., & Richtig, E. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15436 · Cited by 60
Multicellular gene network analysis identifies a macrophage-related gene signature predictive of therapeutic response and prognosis of gliomas
Sun, X., Liu, X., Xia, M., Shao, Y., & Zhang, X. D. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1908-1 · Cited by 58
Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma
Keller, H. R., Zhang, X., Li, L., Schaider, H., & Wells, J. W. (2017) · Oncotarget · doi:10.18632/oncotarget.18523 · Cited by 55
Mutant HRAS as novel target for MEK and mTOR inhibitors
Kiessling, M., Curioni-Fontecedro, A., Samaras, P., Atrott, K., Cosin-Roger, J., Lang, S., Scharl, M., & Rogler, G. (2015) · OncoTarget · doi:10.18632/oncotarget.5619 · Cited by 57
Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity
Hartman, M. L., Sztiller-Sikorska, M., Gajos-Michniewicz, A., & Czyż, M. (2020) · Cells · doi:10.3390/cells9010142 · Cited by 57
ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma
Smit, M. A., Maddalo, G., Greig, K. T., Raaijmakers, L. M., Possik, P. A., van Breukelen, B., Cappadona, S., Heck, A. J. R., Altelaar, M. A. F., & Peeper, D. S. (2014) · Molecular Systems Biology · doi:10.15252/msb.20145450 · Cited by 56
Molecular pathology of malignant melanoma: changing the clinical practice paradigm toward a personalized approach
Bradish, J. R., & Liang Cheng, C. (2014) · Human Pathology · doi:10.1016/j.humpath.2014.04.001 · Cited by 54
Molecular therapeutics for anaplastic thyroid cancer
Pozdeyev, N. V., Rose, M. M., Bowles, D. W., & Schweppe, R. E. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.005 · Cited by 55
Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways
Spain, L. A., Coulton, A., Lobón, I., Rowan, A., Schnidrig, D., Shepherd, S. T. C., Shum, B., Byrne, F., Goicoechea, M., Piperni, E., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1427 · Cited by 57
Synthetic Lethality in Cancer Therapeutics
Beijersbergen, R. L., Wessels, L. F. A., & Bernards, R. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-042016-073434 · Cited by 56
GEMINI: a variational Bayesian approach to identify genetic interactions from combinatorial CRISPR screens
Zamanighomi, M., Jain, S. S., Ito, T., Pal, D., Daley, T., & Sellers, W. R. (2019) · Genome biology · doi:10.1186/s13059-019-1745-9 · Cited by 53
Complete hematologic response of early T-cell progenitor acute lymphoblastic leukemia to the γ-secretase inhibitor BMS-906024: genetic and epigenetic findings in an outlier casePreprint
Knoechel, B., Bhatt, A. S., Li, P., Pedamallu, C. S., Severson, E. A., Gutiérrez, A., Dorfman, D. M., Kuo, F. C., Kluk, M., Kung, A. L., et al. (2015) · Molecular Case Studies · doi:10.1101/mcs.a000539 · Cited by 55
Combination of RAF and MEK Inhibition for the Treatment of BRAF-Mutated Melanoma: Feedback Is Not Encouraged
Chapman, P. B., Solit, D. B., & Rosen, N. X. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.017 · Cited by 54
COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors
Xie, Y., Cao, Z., Wong, E. W. P., Guan, Y., Ma, W., Zhang, J. Q., Walczak, E. G., Murphy, D. A., Ran, L., Sirota, I., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci94840 · Cited by 51
BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association
Vido, M. J., Le, K., Hartsough, E. J., & Aplin, A. E. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.049 · Cited by 55
RNA-seq reveals more consistent reference genes for gene expression studies in human non-melanoma skin cancers
Hoang, V. L. T., Tom, L. N., Quek, X. C., Tan, J. M., Payne, E., Lin, L. L., Sinnya, S., Raphael, A. P., Lambie, D., Frazer, I. H., et al. (2017) · PeerJ · doi:10.7717/peerj.3631 · Cited by 51
Developments in the Space of New MAPK Pathway Inhibitors for BRAF-Mutant Melanoma
Cohen, J. V., & Sullivan, R. J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0836 · Cited by 50
Self-citation
Overcoming treatment resistance in cancer: Current understanding and tactics
Wu, G. J., Wilson, G., George, J., Liddle, C., Hebbard, L., & Qiao, L. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.04.018 · Cited by 49
MEK inhibitors for the treatment of NRAS mutant melanoma
Sarkisian, S., & Davar, D. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s131721 · Cited by 52
BRAF mutation and its inhibitors in sarcoma treatment
Liu, H., Nahar, N., Hassan, S., Liu, X., & Yang, J. (2020) · Cancer Medicine · doi:10.1002/cam4.3103 · Cited by 50
Towards a Unified Model of RAF Inhibitor Resistance
Solit, D. B., & Rosen, N. X. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0961 · Cited by 49
Precision medicine driven by cancer systems biology
Filipp, F. V. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9662-4 · Cited by 52
Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF -Mutant Metastatic Non–Small Cell Lung Cancer
Ortiz‐Cuaran, S., Mezquita, L., Swalduz, A., Aldea, M. D., Mazières, J., Léonce, C., Jovelet, C., Pradines, A., Avrillon, V., Flores, W. R. C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1037 · Cited by 49
Autophagy and the Lysosomal System in Cancer
Kumar, S. G., Sánchez‐Álvarez, M., Lolo, F., Trionfetti, F., Strippoli, R., & Cordani, M. (2021) · Cells · doi:10.3390/cells10102752 · Cited by 47
Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells
Testa, U., Castelli, G., & Pelosi, E. (2017) · Medical Sciences · doi:10.3390/medsci5040028 · Cited by 50
FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma
Lubrano, S., Cervantes‐Villagrana, R. D., Faraji, F., Ramirez, S. I., Sato, K., Adame-Garcia, S. R., Officer, A., Arang, N., Rigiracciolo, D. C., Quiroz, P. Y. A., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.02.001 · Cited by 51
Transposon Mutagenesis Screen Identifies Potential Lung Cancer Drivers and CUL3 as a Tumor Suppressor
Dorr, C. R., Janik, C. L., Weg, M. T., Been, R. A., Bader, J. M., Kang, R. J. D., Ng, B., Foran, L. A., Landman, S. R., O’Sullivan, M. G., et al. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0674-t · Cited by 46
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor–Refractory Metastatic Melanoma
Chen, G., McQuade, J. L., Panka, D. J., Hudgens, C. W., Amin‐Mansour, A., Mu, X. J., Bahl, S., Jané‐Valbuena, J., Wani, K., Reuben, A., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0509 · Cited by 46
Self-citation
Signaling and Immune Regulation in Melanoma Development and Responses to Therapy
Lin, W. M., & Fisher, D. E. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100208 · Cited by 47
Integrated molecular drivers coordinate biological and clinical states in melanoma
Conway, J. R., Dietlein, F., Taylor-Weiner, A. N., AlDubayan, S. H., Vokes, N. I., Keenan, T. E., Reardon, B. M., He, M. X., Margolis, C. A., Weirather, J. L., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-00739-1 · Cited by 44
Self-citation
The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression
Phadke, M. S., Sini, P., & Smalley, K. S. M. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0832 · Cited by 47
Steroid hormone influence on melanomagenesis
Mitkov, M. V., Joseph, R. W., & Copland, J. A. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.09.020 · Cited by 47
The Transcription Factor ETV5 Mediates BRAFV600E-Induced Proliferation and TWIST1 Expression in Papillary Thyroid Cancer Cells
Puli, O. R., Danysh, B. P., McBeath, E., Sinha, D. K., Hoang, N. M., Powell, R. T., Danysh, H. E., Cabanillas, M. E., Cote, G. J., & Hofmann, M.-C. C. (2018) · Neoplasia · doi:10.1016/j.neo.2018.09.003 · Cited by 45
Oncosuppressive miRNAs loaded in lipid nanoparticles potentiate targeted therapies in BRAF-mutant melanoma by inhibiting core escape pathways of resistance
Fattore, L., Cafaro, G., Martile, M. D., Campani, V., Sacconi, A., Liguoro, D., Marra, E., Bruschini, S., Stoppoloni, D., Cirombella, R., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02547-9 · Cited by 47
Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479
Robarge, K. D., Lee, W., Eigenbrot, C. W., Ultsch, M. H., Wiesmann, C., Heald, R. A., Price, S., Hewitt, J. F. M., Jackson, P. S., Savy, P., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.08.008 · Cited by 44
Biology and Treatment of BRAF Mutant Metastatic Melanoma
Kong, B. Y., Carlino, M. S., & Menzies, A. M. (2016) · Melanoma Management · doi:10.2217/mmt.15.38 · Cited by 44
MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors
Motti, M. L., Minopoli, M., Carluccio, G. D., Ascierto, P. A., & Carriero, M. V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124544 · Cited by 45
Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal Cancer
Stewart, G. D., O’Mahony, F. C., Laird, A., Eöry, L., Lubbock, A. L. R., Mackay, A. G., Nanda, J., O’Donnell, M., Mullen, P., McNeill, S. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0207 · Cited by 43
The Biology and Clinical Development of MEK Inhibitors for Cancer
Luke, J. J., Ott, P. A., & Shapiro, G. I. (2014) · Drugs · doi:10.1007/s40265-014-0315-4 · Cited by 42
An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib
Abravanel, D. L., Nishino, M., Sholl, L. M., Ambrogio, C., & Awad, M. M. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.03.026 · Cited by 42
Hinokiflavone induces apoptosis in melanoma cells through the ROS-mitochondrial apoptotic pathway and impairs cell migration and invasion
Yang, S., Zhang, Y., Luo, Y., Xu, B., Yao, Y., Deng, Y., Yang, F., Ye, T., Wang, G., Cheng, Z., et al. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.076 · Cited by 42
Crystal structure of ERK2 G169D mutant
Yin, J., Jaiswal, B. S., & Wang, W. (2018) · Worldwide Protein Data Bank · doi:10.2210/pdb6d5y/pdb · Cited by 42
High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer
Mizuno, S., Ikegami, M., Koyama, T., Sunami, K., Ogata, D., Kage, H., Yanagaki, M., Ikeuchi, H., Ueno, T., Tanikawa, M., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0302 · Cited by 45
Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities
Coppé, J., Mori, M., Pan, B., Yau, C. S. F., Wolf, D. M., Ruiz-Sáenz, A., Brunen, D., Prahallad, A., Cornelissen‐Steijger, P., Kemper, K., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0328-z · Cited by 43
Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase
Kosnopfel, C., Sinnberg, T. W., Sauer, B., Niessner, H., Schmitt, A., Makino, E., Forschner, A., Hailfinger, S., Garbe, C., & Schittek, B. (2017) · Oncotarget · doi:10.18632/oncotarget.16204 · Cited by 39
Precision Medicine in Breast Cancer: Genes, Genomes, and the Future of Genomically Driven Treatments
Stover, D. G., & Wagle, N. (2015) · Current Oncology Reports · doi:10.1007/s11912-015-0438-0 · Cited by 39
Self-citation
Current Status of Biological Therapies for the Treatment of Metastatic Melanoma.
Tang, T., Eldabaje, R., & Yang, L. (2016) · PubMed · Cited by 40
Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer
Clarke, P. A., Roe, T., Swabey, K., Hobbs, S., McAndrew, C., Tomlin, K., Westwood, I. M., Burke, R., van Montfort, R., & Workman, P. (2019) · Oncogene · doi:10.1038/s41388-019-0780-z · Cited by 43
LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells
Ma, Y., Xu, R., Liu, X., Zhang, Y., Li, S., Qiu, X., Cai, S., Zhou, S., Xie, Y., Li, A., et al. (2021) · International Journal of Medical Sciences · doi:10.7150/ijms.51256 · Cited by 39
Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanomain vivo
Bonner, M. Y., Karlsson, I. B., Rodolfo, M., Arnold, R. S., Vergani, E., & Arbiser, J. L. (2016) · Oncotarget · doi:10.18632/oncotarget.7289 · Cited by 40
Identification and functional analysis of SOX10 phosphorylation sites in melanoma
Cronin, J. C., Loftus, S. K., Baxter, L. L., Swatkoski, S., Guček, M., & Pavan, W. J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0190834 · Cited by 39
Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma
Wilson, M. A., Zhao, F., Khare, S., Roszik, J., Woodman, S. E., D'Andrea, K. P., Wubbenhorst, B. S., Rimm, D. L., Kirkwood, J. M., Kluger, H. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1162 · Cited by 39
Self-citation
Epigenetic Mechanisms of Escape from BRAF Oncogene Dependency
Khaliq, M., & Fallahi‐Sichani, M. (2019) · Cancers · doi:10.3390/cancers11101480 · Cited by 39

Authors: Wagle, N., Van Allen, E. M., Treacy, D. J., Frederick, D. T., Cooper, Z. A., Taylor-Weiner, A., Rosenberg, M., Goetz, E. M., Sullivan, R. J., Farlow, D. N., Friedrich, D. C., Anderka, K., Perrin, D., Johannessen, C. M., McKenna, A., Cibulskis, K., Kryukov, G., Hodis, E., Lawrence, D. P., Fisher, S., Getz, G., Gabriel, S. B., Carter, S. L., Flaherty, K. T., Wargo, J. A., & Garraway, L. A.
Affiliations: Broad Institute (US)
Authors' Affiliations: 1Department of Medical Oncology, Dana-Farber Cancer Institute; 2Department of Medicine, Brigham and Women's Hospital; 3Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston; 4Broad Institute of Harvard and MIT; and 5Harvard–MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts
Corresponding author: Wargo, Jennifer A.
Garraway, Levi A.
ORCID: Wagle, Nikhil
Frederick, Dennie T.
Cooper, Zachary A.
Taylor-Weiner, Amaro
Rosenberg, Mara
Sullivan, Ryan J.
Johannessen, Cory M.
McKenna, Aaron
Cibulskis, Kristian
Kryukov, Gregory
Hodis, Eran
Lawrence, Donald P.
Getz, Gad
Gabriel, Stacey B.
Carter, Scott L.
Flaherty, Keith T.
Wargo, Jennifer A.
Garraway, Levi A.
Venue: Cancer Discovery
Publisher: American Association for Cancer Research (AACR)
Published: 2014-01-01
Volume: 4
Issue: 1
Pages: 61-68
ISSN: 2159-8274 (ISSN-L)
2159-8290
DOI: 10.1158/2159-8290.cd-13-0631
PMC: PMC3947296
OpenAlex: W2103557568
Cited by: 478
References: 27
Citations by year: 2026: 6 · 2025: 19 · 2024: 19 · 2023: 18 · 2022: 33 · 2021: 29 · 2020: 39 · 2019: 47 · 2018: 38 · 2017: 54 · 2016: 44 · 2015: 74 · 2014: 55
FWCI: 26.30
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Discovery (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (DP2OD002750)
National Human Genome Research Institute (U54HG003067)
National Cancer Institute (P50-CA-93683, R33CA155554, P01 CA163222 01A1, P50CA093683, T32CA009172, P30CA016672, P01CA163222)
National Institute of General Medical Sciences (T32GM007753)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords: BRAF-mutant melanoma, acquired drug resistance, dabrafenib, trametinib, MEK2, MAPK pathway alterations, ERK inhibition, targeted therapy resistance, resistance mechanisms
MeSH terms: Aged, Antineoplastic Agents, Humans, Imidazoles, Male, Melanoma, Middle Aged, Mutation, Oximes, Pyridones, Pyrimidinones, Skin Neoplasms, Signal Transduction, Drug Resistance, Neoplasm, Mitogen-Activated Protein Kinases, Mitogen-Activated Protein Kinase Kinases, Protein Kinase Inhibitors, raf Kinases, Proto-Oncogene Proteins B-raf

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

MAP Kinase Pathway Alterations in BRAF -Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks